Literature DB >> 35663100

Inflammation in Myeloid Malignancies: From Bench to Bedside.

Eli M Soyfer1, Angela G Fleischman2,3.   

Abstract

Myeloid malignancies, stemming from a somatically mutated hematopoietic clone, can cause a wide variety of clinical consequences, including pancytopenia in myelodysplastic syndrome, overproduction of three myeloid lineages in myeloproliferative neoplasm, and the rapid growth of immature hematopoietic cells in acute myeloid leukemia (AML). It is becoming clear that inflammation is a hallmark feature of clonal myeloid conditions, ranging from clonal hematopoiesis of indeterminate potential to AML. Fundamental findings from laboratory research on inflammation in myeloid malignancies has potential implications for diagnosis, prognostication, and treatment in these diseases. In this review, we highlighted some pertinent basic science findings regarding the role of inflammation in myeloid malignancies and speculated how these findings could impact the clinical care of patients. © Innovative Healthcare Institute 2021.

Entities:  

Year:  2021        PMID: 35663100      PMCID: PMC9138438          DOI: 10.36401/JIPO-21-3

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN: 2590-017X


  70 in total

1.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

2.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

3.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

4.  Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Malin Hultcrantz; Åsa R Derolf; Ola Landgren; Lynn R Goldin
Journal:  J Clin Oncol       Date:  2011-06-20       Impact factor: 44.544

5.  Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.

Authors:  Judith E Karp; Ivana Gojo; Roberto Pili; Christopher D Gocke; Jacqueline Greer; Chuanfa Guo; David Qian; Lawrence Morris; Michael Tidwell; Helen Chen; James Zwiebel
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

6.  Toll-like receptor alterations in myelodysplastic syndrome.

Authors:  Y Wei; S Dimicoli; C Bueso-Ramos; R Chen; H Yang; D Neuberg; S Pierce; Y Jia; H Zheng; H Wang; X Wang; M Nguyen; S A Wang; B Ebert; R Bejar; R Levine; O Abdel-Wahab; M Kleppe; I Ganan-Gomez; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-06-14       Impact factor: 11.528

7.  Risks of myeloid malignancies in patients with autoimmune conditions.

Authors:  L A Anderson; R M Pfeiffer; O Landgren; S Gadalla; S I Berndt; E A Engels
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

Review 8.  Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype.

Authors:  David A Sallman; Thomas Cluzeau; Ashley A Basiorka; Alan List
Journal:  Front Oncol       Date:  2016-06-16       Impact factor: 6.244

Review 9.  Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.

Authors:  Jack W Singer; Angela Fleischman; Suliman Al-Fayoumi; John O Mascarenhas; Qiang Yu; Anupriya Agarwal
Journal:  Oncotarget       Date:  2018-09-07

10.  Cancer therapy shapes the fitness landscape of clonal hematopoiesis.

Authors:  Ryan N Ptashkin; Teng Gao; Ahmet Zehir; Elli Papaemmanuil; Kelly L Bolton; Lior Braunstein; Sean M Devlin; Daniel Kelly; Minal Patel; Antonin Berthon; Aijazuddin Syed; Mariko Yabe; Catherine C Coombs; Nicole M Caltabellotta; Mike Walsh; Kenneth Offit; Zsofia Stadler; Diana Mandelker; Jessica Schulman; Akshar Patel; John Philip; Elsa Bernard; Gunes Gundem; Juan E Arango Ossa; Max Levine; Juan S Medina Martinez; Noushin Farnoud; Dominik Glodzik; Sonya Li; Mark E Robson; Choonsik Lee; Paul D P Pharoah; Konrad H Stopsack; Barbara Spitzer; Simon Mantha; James Fagin; Laura Boucai; Christopher J Gibson; Benjamin L Ebert; Andrew L Young; Todd Druley; Koichi Takahashi; Nancy Gillis; Markus Ball; Eric Padron; David M Hyman; Jose Baselga; Larry Norton; Stuart Gardos; Virginia M Klimek; Howard Scher; Dean Bajorin; Eder Paraiso; Ryma Benayed; Maria E Arcila; Marc Ladanyi; David B Solit; Michael F Berger; Martin Tallman; Montserrat Garcia-Closas; Nilanjan Chatterjee; Luis A Diaz; Ross L Levine; Lindsay M Morton
Journal:  Nat Genet       Date:  2020-10-26       Impact factor: 41.307

View more
  3 in total

1.  Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas.

Authors:  Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 2.  Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis.

Authors:  Satoru Shinriki; Hirotaka Matsui
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

3.  A Case of Recurrent Myocarditis after COVID-19 Vaccination due to Acute Myeloid Leukemia.

Authors:  Isabelle Dobronyi; Danielle Porter; Idan Roifman; Ady Orbach; Bradley H Strauss
Journal:  CJC Open       Date:  2022-10-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.